| N (%) |
---|---|
Year published | |
 2016 | 1 (1.8) |
 2017 | 2 (3.5) |
 2018 | 3 (5.3) |
 2019 | 2 (3.5) |
 2020 | 11 (19.3) |
 2021 | 16 (28.1) |
 2022 | 20 (35.1) |
 2023 | 2 (3.5) |
WHO regiona | |
 African | 36 (60.0) |
 Western Pacific | 7 (11.7) |
 South-East Asian | 7 (11.7) |
 Americas | 9 (15.0) |
 Eastern Mediterranean | 2 (3.3) |
 European | 2 (3.3) |
Study settinga | |
 Healthcare | 52 (86.7) |
 Community | 11 (18.3) |
 Policy | 4 (6.7) |
Target health condition | |
 Cancer | 1 (1.7) |
 Chronic non-communicable disease | 7 (11.7) |
 General | 9 (15.0) |
 Infectious disease | 19 (31.7) |
 Maternal and child health | 10 (16.7) |
 Mental health and substance use | 10 (16.7) |
 None | 2 (3.3) |
 Sexual and reproductive health | 2 (3.3) |
Study type | |
 Protocol | 17 (28.3) |
 Empirical | 43 (71.7) |
Study populationa | |
 Patients | 31 (51.7) |
 Providers | 43 (71.7) |
 Policymakers | 14 (23.3) |
 Community members | 8 (13.3) |
 Researchers | 6 (10.0) |
Process evaluation or formative study designa | |
 Formative implementation strategy design | 17 (28.3) |
 Formative strategy design and prospective process evaluation | 2 (3.3) |
 Prospective process evaluation | 20 (33.3) |
 Retrospective strategy specification | 9 (15.0) |
 Retrospective process evaluation | 3 (5.0) |
 None | 9 (15.0) |
Impact evaluation study design | |
 Cluster RCT | 9 (15.0) |
 Individual RCT | 2 (3.3) |
 QE without control | 13 (21.7) |
 QE with control | 6 (10.0) |
 Prospective cohort | 5 (8.3) |
 Retrospective cohort | 1 (1.7) |
 None | 24 (40.0) |
IndePENDENT VARIABLE | |
 No Comparison | 33 (0.55) |
 Intervention | 13 (21.7) |
 Implementation strategy | 14 (23.3) |
 Context | 0 |
Implementation research theory or framework useda | |
 Determinants | 36 (60.0) |
 Process | 7 (11.7) |
 Evaluation | 24 (40.0) |
Implementation outcomes measureda | |
 Acceptability | 27 (45.0) |
 Adoption | 29 (48.3) |
 Appropriateness | 16 (26.7) |
 Cost | 16 (26.7) |
 Feasibility | 16 (26.7) |
 Fidelity | 26 (43.3) |
 Penetration | 19 (31.7) |
 Sustainability | 17 (28.3) |
 Health outcomes measured | 25 (41.7) |